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ABSTRACT
Genome-widemicroarraytechnologyhasfacilitatedthesystematicdiscoveryofdiag-
nosticbiomarkersofcancersandotherpathologies.However,meta-analysesofpub-
lishedarraysoftenuncoversigniﬁcantinconsistenciesthathinderadvancesinclinical
practice. Here we present an integrated microarray analysis framework, based on
a genome-wide relative signiﬁcance (GWRS) and genome-wide global signiﬁcance
(GWGS) model. When applied to ﬁve microarray datasets on melanoma published
between 2000 and 2011, this method revealed a new signature of 200 genes. When
these were linked to so-called ‘melanoma driver’ genes involved in MAPK, Ca2C,
and WNT signaling pathways we were able to produce a new 12-gene diagnostic
biomarker signature for melanoma (i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, TNC,
CXCL13, COL11A1, CHP2, SHC4, PPP2R2C, and WNT4). We have begun to exper-
imentally validate a subset of these genes involved in MAPK signaling at the protein
level, including CXCL13, COL11A1, PTPRF and SHC4 and found these to be over-
expressedinmetastaticandprimarymelanomacellsin vitroandin situcomparedto
melanocytes cultured from healthy skin epidermis and normal healthy human skin.
While SHC4 has been reported previously to be associated to melanoma, this is the
ﬁrst time CXCL13, COL11A1, and PTPRF have been associated with melanoma on
experimental validation. Our computational evaluation indicates that this 12-gene
biomarkersignatureachievesexcellentdiagnosticpowerindistinguishingmetastatic
melanoma from normal skin and benign nevus. Further experimental validation of
the role of these 12 genes in a new signaling network may provide new insights into
theunderlyingbiologicalmechanismsdrivingtheprogressionofmelanoma.
Subjects Bioinformatics, Cell Biology, Computational Biology, Genomics, Dermatology
Keywords Gene biomarker, Microarray, Bioinformatics, Genome, Nevi, Skin, Melanocytes,
Melanoma, Metastasis, Immunochemistry
INTRODUCTION
Melanoma is a cancer involving the transformation and uncontrolled growth of
melanocytes (Miller & Mihm, 2006) and can originate in skin, mucosa, uvea, and
leptomeninges (Eigentler & Garbe, 2006). Since the mid-1960s the reported incidence
of melanoma has increased every year by up to 8% (Lens, 2008). Malignant melanoma
metastasizes quickly and only 14% of patients with metastatic disease can expect to live
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analysis. PeerJ1:e49; DOI10.7717/peerj.49for 5 years (Miller & Mihm, 2006). While some new therapies are coming on stream
(e.g., ipilimumab) (Postow et al., 2012), the cure rate largely depends on early detection
and tumor removal by surgery. Metastatic potential is mainly related to tumor thickness
(Rigel&Carucci,2000),andagreaterthan90%curerateispossibleifthetumorislessthan
1mmthickwhenremoved(Gremeletal.,2009).
A robust genetic marker signature should greatly advance both the diagnosis and
targeted treatment of melanoma in clinical practice. To that end, microarray technology
has been used as an advanced high-throughput strategy for the discovery of diagnostic
gene signatures of human diseases at the genome-wide scale. The genome-wide discovery
of such a signature would provide important insights into the underlying biological
mechanisms driving melanomagenesis. A signiﬁcant amount of microarray data has been
produced and deposited in publically-available data repositories recently, including Gene
Expression Omnibus (GEO) (Barrett et al., 2011) and ArrayExpress Archive (Parkinson et
al., 2011). These repositories allow scientists to advance the discovery of diagnostic and
prognosticgenesignaturesbymeansofdataintegrationandbioinformaticsanalysis.Lukk
etal.(2010)constructedaglobalmapofhumangeneexpressionbyintegratingmicroarray
data from 5,372 human samples representing 369 diVerent cell and tissue types, disease
states and cell lines. While microarray technology has also been applied to comparative
analyses of diVerent stages in melanoma development and have identiﬁed various gene
signatures (Hoek, 2007), there is poor congruence between gene signatures generated
by diVerent microarray-based melanoma studies (John et al., 2008; Bittner et al., 2000;
T´ ım´ ar,GyorVy&R´ as´ o,2010).Unsurprisinglytherefore,microarray-basedmelanomagene
biomarkers have had poor translation to clinical practise, and melanoma diagnosis is still
basedonclinicalandhistopathologicalfeaturesofthetumor(Schrammetal.,2011).
Meta-analysis approaches have been used to seek out and reveal often latent data
complexity and connectivity, and so have the potential to increase the robustness of
data interpretation (Ramasamy et al., 2008; Hong & Breitling, 2008; Cochran & Conn,
2008). Choi and co-workers (Choi et al., 2003) have demonstrated that meta-analysis
can positively inﬂuence statistical signiﬁcance by amending the false negative rate of
individual studies. Using this approach, Rhodes and colleagues successfully identiﬁed
50 over-expressed and 103 under-expressed genes in an enhanced signature of prostate
cancer (Rhodes et al., 2002). Similarly, Parmigiani and co-workers built a cross-study
comparison for lung cancer (Parmigiani et al., 2004), while Park and Stegall revealed the
true involvement of cytokine genes of human kidney disease by combining their own
microarraydatawithotherpublicsources(Park&Stegall,2007).
Two very recent reviews and meta-analyses of melanoma microarray studies (T´ ım´ ar,
GyorVy & R´ as´ o, 2010; Schramm et al., 2011) revealed some strikingly contradictory
results. T´ ım´ ar et al. compared signatures derived from four microarray datasets of human
melanoma tissue, but found very little overlap between the signatures, both within and
between these studies (T´ ım´ ar, GyorVy & R´ as´ o, 2010). They attributed much of this lack
of congruence to sample heterogeneity. By adding 5 additional studies, Schramm and
colleagues however demonstrated some signiﬁcant over-represented functions among the
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response. A ‘leave-one-out’ cross validation with a low average error rate (28%) across all
validation expression data was achieved for the gene signature of Mann, Pupo & Campain
(2013).
To identify a more robust gene biomarker signature for melanoma we propose a new
model that measures the genome-wide relative signiﬁcance (GWRS) and genome-wide
global signiﬁcance (GWGS) of gene expression. This new model enables the integrative
analysis of microarray datasets produced by diVerent platforms and protocols. We
examined microarray-based melanoma studies published between 2000 and 2011 and
retrieved ﬁve microarray datasets that study diVerential gene expression between normal
skinand/orbenignneviandmetastaticmelanoma(Hoeketal.,2004;Smith,Hoek&Becker,
2005; Riker et al., 2008; Scatolini et al., 2010; Rose et al., 2011). The integrated analysis
of these ﬁve microarray datasets identiﬁed a robust biomarker signature of 12 genes for
melanoma, which includes six previously-unreported genes. Our integrated investigation
combinesacomputationalapproachwithexperimentalvalidation.
METHODS
Microarray datasets
This study examines the diVerential expression of genes between normal skin and/or
benign nevi, and metastatic melanoma using a meta-analysis approach. The experimental
protocol of this study is shown in Fig. 5 and commenced with the identiﬁcation of 16
microarray studies on metastatic melanoma published 2000 to 2011. Microarray data
included in these studies are shown in Table S5. In the current study, we focused our
attention on the diVerential gene expression between normal skin and/or benign nevi
and metastatic melanoma. On this basis four microarray datasets were extracted (GEO
access number: GSE7553, GSE4587, GSE4579, and GSE12391). An additional GSE22301
dataset was extracted from Rose et al. (2011), but while this study did not provide a gene
signature of metastatic melanoma (and so was not included in the meta-analysis of 16
studies)itdidinclude14samplesofmetastaticmelanomadataandsowasincludedinour
integrative analysis. Thus, a total of ﬁve microarray datasets of normal and/or benign nevi
andmetastaticmelanomawereusedinthisstudy(TableS6).
Genome-wide relative signiﬁcance (GWRS) and Genome-wide
global signiﬁcance (GWGS) for integrated analysis of cross-
laboratory microarray data
A relatively simple method of integrative meta-analysis was proposed by Rhodes et al.
in 2002 that combines independent microarray studies based on the p-value of each
individualgene:
sp D  
n X
iD1
2log.pi/
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 3/23where pi;i D 1–n, is the p-value of a gene in the i-th independent study. However, this
method has at least two signiﬁcant limitations: (1) many microarray studies are based on
asmallnumberofsamples,forwhichthep-valuecanthereforebeproblematicand(2)the
large variation in p-values across diVerent studies leads to the data with smallest p-value
determiningtheoutcomeofSp.
We propose a new approach based on measuring the genome-wide relative signiﬁcance
(GWRS) and genome-wide global signiﬁcance (GWGS) of expressed genes. We measure
theGWRSofageneusingitsrankingposition(Jurmanetal.,2008)onagenome-widescale
(r value) based on a diVerential expression measure, which can be the fold change, t-test
p-value, SAM (Signiﬁcance Analysis of Microarray data) p-value etc. Most existing meta
analysis methods focus on the top-k genes (e.g. Jurman et al., 2008), while our method
counts the ranking of genome-wide genes in total. Compared to the model of Rhodes and
co-workers the proposed approach possess two important enhancements: (1) it can apply
multiple diVerent methods for measuring the degree of diVerential expression of a gene
(e.g. fold change, t-test, Anova or SAM p-values) and (2) it uses a ranking r value instead
oftheteststatistic(i.e.,foldchange,orp-value)toavoidtheinﬂuenceofhighvariationtest
statistics.
Data preparation
Pre-processingofmicroarraydataisperformedbyextractingtheexpressionvalueforeach
individual gene from the associated probe-sets. When a probe-set is mapped to multiple
genes,e.g.‘209994 s at’associatedtotwogenes‘ABCB1/ABCB4’inGSE4570,bothgenes
aregiventheexpressionofthe‘209994 s at’probe-set.
For a gene appearing in multiple probe-sets, the most signiﬁcant diVerential expressed
probe-sets are assigned to this gene. We tested the results of using mean-, median-,
and maxim-based methods to deal with the situations were multiple probe-sets are
associated to a gene. We observed that the maxim-based method was able to retrieve
the most signiﬁcant probe-set of a gene, and would reﬂect our aim of extracting the most
competitive genes across multiple studies. By contrast, use of a mean- or median-based
probe-setvalueofagenewoulddragtheexpressionleveldown,andmayintroducebiasin
follow-up analysis. As a result, a list of unique genes (G) from the datasets was retrieved.
The number of datasets was denoted by n, while the number of unique genes across n
datasets was denoted by m, i.e. m D jGj. The value ‘NA’ was applied in cases where a gene
is absent from an individual study. We removed a gene from G where NA is bigger than
 ( D 2 in this study), i.e. a gene was removed if it is absent for more than two of ﬁve
datasets.Thisresultedinm D 24,097andn D 5.
Measuring the GWRS of genes in each single microarray database
For each gene in the list of unique genes (G), we measured the degree of diVerential
expression that can be measured by fold-change, t-test (p-value), SAM or other statistical
test. However, fold-change is used in the current study, as our computational evaluation
indicated that this produces more reliable results, probably due to the limited number
of samples in some of the datasets. For each gene in G, we assigned a rank number
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diVerential expression i.e. a gene with a high degree of diVerential expression was ranked
morehighlyandsowithasmallerrankingnumber.Anmnmatrix(R)wasthuscreatedin
whichrij istherankingnumberofthei-thgeneinthej-thdataset.WemeasuretheGWRS
ofthei-thgeneinthej-thdatasetby:
sij D  2 log
rij
m

whererij;i D 1–m;j D 1–n,istheranknumberofthei-thgeneinthej-thstudy.Therange
of GWRS value (sij) is between 0 and  2log.1=m/. For a gene with ‘NA’ value the sij is set
tobe‘NA’.
Measuring the GWGS of a gene across multiple microarray
datasets
WeestimatedtheGWGS(sr
i)ofagenebasedonitscorrespondingGWRSacrossndatasets,
by
sr
i D
n X
jD1
!jsij
where !j represents the relative weight of the j-th dataset, and
Pn
jD1!j D 1. The value of
weight (!j) can be assigned based on the data quality of the j-th datasets (e.g. the level
of data noise. The value of !j can also be used to reﬂect the diVerential importance of
biopsy versus cell line samples that biological scientists may wish to take into account.
In this study, we treated all the dataset equally, thus the weight of each datasets was
set equally to be 1=n for j D 1–n. We also selected only the top 200 genes from the full
gene list for further analysis (i.e. selected genes with the greatest sr value) by empirical
evaluation of the classiﬁcation performance (accuracy ratio). This was determined using
the ‘wrapper-feature selection’ after multiple rounds of gene addition (ranging from 20
genes up to 500 genes) in order to distinguish melanoma from normal skin/benign nevus.
Weobservedthatusingmorethan200genesyieldednoimprovementinclassiﬁcationratio
values, and so we consider 200 genes as an optimal gene set with the smallest number of
genesthatstillcanachieveasimilarlevelofclassiﬁcationperformance.
Pathway analysis
We performed a pathway analysis to assess functional relevance of the new 200 gene
signaturebasedontheDAVIDdatabase(Hosacketal.,2003).DAVIDprovidesausefultool
to analyze large gene lists, including via gene ontology and pathway analysis. We applied
our top 200 genes to this database in order to detect potentially over-represented KEGG
pathways. Before inputting into the DAVID database, we extracted the corresponding
probe-sets of the 200 genes for the corresponding microarray platforms of each dataset.
In comparison with the gene signature in the original 16 studies, we also extracted their
associated probe-sets. We retrieved 31 pathways from the KEGG database where 12
genes (i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, TNC, CXCL13, COL11A1, CHP2, SHC4,
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 5/23PPP2R2C, and WNT4) in this 200-gene signature were found to closely interact with the 4
melanomadrivergenes(seeResultssection).
Immunocytochemistry (ICC)
Primary epidermal melanocyte (EM) (female 44y), moderately pigmented human
melanoma cells (FM55), and highly pigmented human melanoma cells (FM94)
(melanoma cells were a gift of Dr Janis Ancans, University of Latvia) were cultured as
previously described (Gledhill et al., 2010). The cells were ﬁxed in ice-cold methanol
(Sigma, Poole, Dorset, UK) for 10 min before air drying and rehydration in PBS. The cells
were blocked with 10% donkey serum (DS) for 1 h, washed with PBS before incubation
with respective primary antibodies to four test antigens from this 12-gene signature.
These included: COL11A1 (Abcam, ab64883), CXCL13 (R & D Systems, AF801), PTPRF
(NeuroMab, 75-193), SHC4 (Proteintech, 12641-1-AP), which were incubated overnight
at 4 C followed by secondary antibody (1:300) for 1 h (donkey anti-goat (Invitrogen,
A11055), donkey anti-mouse (Invitrogen, A21202), donkey anti-rabbit (Invitrogen,
A21206), Alexa green). The slides were cover-slipped by VECTASHIELD mounting
medium withDAPI and photographed usinga Nikon Eclipse 80iﬂuorescence microscope
and imaged with a Nikon Digital Sight DS-U1 camera. A full assessment of all 12 proteins
inourmelanomasignatureisbeyondthescopeofthecurrentstudy,butwillbeassessedin
detailinafollow-upstudies.
Double immunohistochemistry (IHC)
ParaYn-embeddedprimarymelanomain situ(nose)andmetastaticmelanoma(lowerleg)
weredeparaYnizedandboiledinsodiumcitratebuVer(10mM,0.05%Tween20,pH6.0)
for antigen retrieval. Acetone-ﬁxed cryosections of normal human facial skin (Female 52
yrs) were used as control samples. All tissues were blocked with 10% donkey serum (DS)
for 1 h, washed with PBS before 2 h incubation with NKi/beteb antibody raised against
themelanocytelineage-speciﬁcmarkergp100asapositivepigmentcellcontrol(Monosan;
Mon7006-1)(1:15)followedbyeachofthe4testantibodiesatroomtemperature.
Data Access
The microarray data used in this study were retrieved from Gene Expression Omnibus
(GEO) with the following access numbers: GSE4570, GSE4587, GSE7553, GSE12391, and
GSE22301. The 16 signatures of melanoma reported in the literature between 2000 and
2011wereextractedfromtheassociatedpublicationandispresentedinTableS2.
RESULTS
Gene signatures of melanoma (2000 to 2011) share few common
genes
A meta-analysis conducted on gene signatures of metastatic melanoma reported in 16
independent microarray-based studies (ranging from 5 to 589 genes/study) from 2000
to 2011, showed remarkably few shared genes (Table 1, and Supplementary Information
TableS1).
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Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 7/23There were 84 genes common to two of the signatures (Scatolini et al., 2010; Jaeger et
al., 2007), while 14 common genes appeared in three studies (Scatolini et al., 2010; Jaeger
et al., 2007; Riker et al., 2008). Strikingly, while there were only 2 genes (KRT15, RORA) in
commoninfourofthe16studies(Scatolinietal.,2010;Jaegeretal.,2007;Rikeretal.,2008;
Smith,Hoek&Becker,2005),wehaverecognizedfourgenesinour200geneset(i.e.KRT15,
MAGEA6, RORA and SULF1) that appeared in 4 diVerent studies of the 16. No gene was
common in ﬁve or more independent studies (Table S2). This ﬁnding suggested that there
maybesomefundamentalissueswitheitherthemannerinwhichthesemicroarraystudies
weredesigned,orwiththemeta-analysesconducted.Onthisbasiswesetaboutdesigninga
newmorerobustmodelformeta-analysis.
Integrated analysis of cross-laboratory microarray data reveal a
new melanoma gene signature
Weappliedournewapproachtointegrativelyanalyzeﬁveindependentmicroarraystudies
(Hoek et al., 2004; Smith, Hoek & Becker, 2005; Riker et al., 2008; Scatolini et al., 2010;
Rose et al., 2011) (see Methods). The genome wide ‘global signiﬁcance’ or GWGS of a
gene (i.e., across all ﬁve datasets) was measured by the GWGS (sr) as deﬁned above (see
Methods). A gene with a large sr value is considered to be signiﬁcant across multiple
independent studies (i.e., globally signiﬁcant). The 200 genes with largest sr value were
selectedasthestartingpointforournewproposedgenesignatureofmelanoma,aslistedin
Table2andTableS3.Thissetof200signaturegeneswasempiricallydetermined,basedon
theclassiﬁcationaccuracyratioaftervariousroundsofgeneadditions(usingthe‘wrapper
feature selection’ approach) in order to distinguish melanoma from normal skin cells
and/orbenignnevus.Astheclassiﬁcationaccuracyratiowasimprovedverylittlebyadding
morethan200genes,weappliedthisgenesetasthesmallestnumberofgenestoretainthe
optimalclassiﬁcationaccuracyperformance.
Validation of a new 200-gene signature based on experimental
studies reported in the literature
The200genesfoundtohavegenome-wideglobalsigniﬁcanceinourstudywerecompared
with the gene signatures identiﬁed in previously-published reports (Table S5). Our new
200-gene signature was ﬁrst validated by (i) comparing it with 16 signatures proposed
in the referred to set of microarray studies (Table S1), (ii) checking if any experimental
validation of these genes was published in the literature (PubMed, last access: 16 April
2012). This analysis revealed that (a) 85 genes in our 200-gene signature were reported
in at least one of the 16 microarray studies, and (b) 21 genes of the 200-gene signature
were reported in both microarray studies and wet-lab experimental studies (Table S4,
labeled yellow background). We also found that 38 genes of this 200-gene signature were
not reported in any of the 16 reference studies, but had in fact been previously validated
in independent wet-lab studies (Table S4 and discussion section). Importantly, our new
genesignaturereportedanadditionalsubsetof77genesthatwerenotpreviouslyreported
anywhereintheliteratureinassociationwithmelanoma(Fig.1).Therankingpositionsof
these77genesshowsthat39%appearinthetop100and34%inbottom50(seeTableS7).
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 8/23Table 2 The 200 genes with largest sr values that were selected as the proposed gene signature of
melanoma.
No. Genes No. Genes No. Genes No. Genes
1 DCD 51 GAGE7 101 DKFZP434B061 151 AQP3
2 MAGEA3 52 DGAT2 102 PPP1R14C 152 C1orf116
3 MAGEA2 53 FGFR3 103 AKR1C3 153 RGS4
4 MAGEA2B 54 MICALCL 104 C19orf33 154 GRHL3
5 CSAG3 55 KRT15 105 FGFR2 155 GPR115
6 CSAG2 56 CTAG2 106 IGL@ 156 SERPINA3
7 GAGE12F 57 ANK3 107 SERPINB5 157 LAD1
8 GAGE12G 58 HMGA2 108 CYP3A5 158 FLI37464
9 GAGE12I 59 MYOZ2 109 LEP 159 HLA-DRB4
10 GAGE2A 60 AADACL2 110 CHST6 160 TMEM79
11 GAGE2B 61 SCGB2A2 111 TF 161 ZNF750
12 GAGE2C 62 ISG20 112 MIA 162 IGHV4-31
13 GAGE2E 63 DST 113 HLA-DQB1 163 TP63
14 GAGE4 64 IL13RA2 114 GPR87 164 LOC124220
15 CTAG1B 65 APOC2 115 RHBDL2 165 RASGRF1
16 KRT77 66 TNC 116 SGPP2 166 KRT5
17 THRSP 67 FMN2 117 SCARA5 167 LAMB4
18 CTAG1A 68 SHC4 118 SAA1 168 SCML4
19 GAGE5 69 FSTL5 119 RNASE2 169 CYP4B1
20 GAGE6 70 PTPRF 120 SLAMF7 170 HLA-DRB3
21 MAGEA12 71 KRTAP19-1 121 SAA2 171 NEBL
22 MAGEA6 72 CXCL13 122 PPP2R2C 172 IGSF9
23 XAGE1A 73 GAGE1 123 GBP5 173 KLK11
24 XAGE1B 74 EYA1 124 AKR1C1 174 CHP2
25 XAGE1C 75 HLA-DRB2 125 ENTHD1 175 MAGEA10
26 XAGE1D 76 LOC100133484 126 EPHA3 176 CYP26B1
27 XAGE1E 77 LOC100133661 127 KRT6B 177 EREG
28 PRAME 78 LOC100133811 128 CCDC3 178 DLX1
29 C4orf7 79 LOC730415 129 BTBD16 179 LOC285986
30 GAGE12B 80 ZNF749 130 ANKRD35 180 TRIM7
31 GAGE12C 81 KRT14 131 HLA-DQA1 181 GAD1
32 GAGE12D 82 IGFL2 132 C10orf116 182 LOR
33 GAGE12E 83 SCEL 133 JUP 183 EXPH5
34 GAGE12H 84 GAGE3 134 IGFBP5 184 TMEM154
35 GAGE12J 85 GATA3 135 KRT25 185 LASS3
36 GAGE2D 86 DSP 136 SULF1 186 HLA-DRB5
37 GAGE8 87 WNT4 137 TKTL1 187 LOC100126583
38 WFDC5 88 TACSTD2 138 IL1F7 188 CYP4F8
39 IL8 89 CAPNS2 139 C6orf218 189 SDC1
40 COL17A1 90 MAL2 140 HEY1 190 SCGB1D2
41 FOXQ1 91 DGAT2L3 141 MGST1 191 RORA
42 ZIC1 92 PIP 142 ABCA13 192 SH3RF2
(continued on next page)
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No. Genes No. Genes No. Genes No. Genes
43 ELMOD1 93 AKR1C2 143 RAPGEFL1 193 LGALS7
44 ELOVL3 94 IGF2 144 TFPI2 194 MMP1
45 SERPINA12 95 MPP7 145 TRIM29 195 MAGEC1
46 DSC3 96 IGHG1 146 ALDH1A3 196 FRMD5
47 MAGEA1 97 NMU 147 ATP6V1C2 197 SERPINB7
48 DMKN 98 EGFR 148 COL11A1 198 FGF13
49 INS-IGF2 99 APOC4 149 RSPO1 199 LOC645323
50 C1orf172 100 MGP 150 PLA1A 200 COL9A3
Figure1 Validation of the proposed 200-gene signature. The 200 signature gene set is taken from the full
list of genes associated with melanoma and was selected for further analysis based on their classiﬁcation
accuracy ratio (i.e. genes with the greatest sr value).
Thesegenesmayrepresent‘novelgenes’astheywerenotpreviouslyidentiﬁedinpublished
microarray studies. We further investigated the characteristics of the 85 genes reported in
at least 1 of the 16 reference microarray studies (Table S3). Forty-four were reported in
2 studies, while 17 genes have been reported in 3 of the 16 studies (Table S3). KRT15,
MAGEA6, RORA and SULF1 were the most frequently reported genes appearing in 4 of
the 16 studies. Thus, using our method, we are able to pick up 4 of the 7 most frequently
reportedgenesinthe16studiesbyusingjustourtop200genes(i.e.,30%lessthanthenext
best list of 308 genes in Jaeger et al. (2007)). In this way the methodology to select the top
200 genes in our study is more powerful than previously reported on the component 16
publishedsignaturesusedforthesourcedata(Table1).
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 10/23Interaction of a new 200-gene signature with melanoma ‘driver’
genes informs a new signaling network in melanoma
Weinvestigatedtheinteractionbetweengeneswithinour200-genesignaturewiththefour
known melanoma ‘driver’ genes (i.e., NRAS, BRAF, MITF and cKIT). Of these driver
genes, NRAS is mutated in 13–25% of melanoma cases (Goel et al., 2006; Schubbert,
Shannon & Bollag, 2007), while BRAF (located downstream of NRAS), is mutated in up
to45%ofmalignantmelanomas(Hocker&Tsao,2007;Flaherty&McArthur,2010).MITF,
amastertranscriptionfactorinmelanocytefunction,cooperateswhenmutatedwithBRAF
in melanomagenesis (Garraway et al., 2005; Taylor et al., 2011). Recent studies show that
mutant cKIT can activate the Ras/Raf/Mek/Erk pathway and also activate MITF (Monsel
et al., 2009; Phung et al., 2011). The four well-known melanoma driver genes did not
appear on our list. This is due most likely to these four driver genes being associated with
melanomaatthegenemutationlevel,ratherthanatthegeneexpressionlevel.
We retrieved 31 pathways from the KEGG database where 12 genes in our proposed
200-gene signature were found to closely interact with the 4 melanoma driver genes in
the MAPK, Ca2C and WNT signaling pathways (Table 3). These 12 genes are EGFR,
FGFR2, FGFR3, IL8, PTPRF, TNC, CXCL13, COL11A1, CHP2, SHC4, PPP2R2C, and
WNT4. Based on these interactions we propose a new signaling network for melanoma
(Fig. 2). Of these 12 genes, CXCL13, SHC4, WNT4 and CHP2 were detected only using
our computational method (i.e., not reported before in melanoma microarray studies)
but exhibit important positions in melanoma driver gene signaling pathways (Fig. 2). The
biologicalpathwaysinvolvingchemokinereceptors,WNT,Ca2C andMAPKsignalingwill
haveimplicationsformelanomagenesisandmetastaticprogression.
Experimental validation of a MAPK pathway-associated subset in
our 12-gene melanoma signature
Four genes in our proposed 12-gene biomarker signature that appear in the MAPK sig-
naling pathway (i.e., COL11A1, CXCL13, PTPRF, and SHC4) were selected for laboratory
validation. Note that COL11A1, CXCL13, and PTPRF have not previously been reported
to be associated with melanoma experimentally. COL11A1, CXCL13, PTPRF, and SHC4
werefoundtobeover-expressedintwohumanmelanomacelllines(i.e.,FM55andFM94)
compared to normal human epidermal melanocytes in vitro (Fig. 3). A signiﬁcant degree
of heterogeneity was observed in the expression pattern for these markers. For example,
COL11A1, a secreted collagen protein, was observed at low levels in the cytoplasm of
normalmelanocytes,butmoreintenselyintheperikayonofmoderately-pigmentedFM55
melanoma cells, and unexpectedly exhibited a nuclear/nuclear membrane association
in the pigmented FM94 melanoma cells. Similarly, a weak cytoplasmic localization of
CXCL13 in normal melanocytes appeared to shift towards the perikayon and nucleus
of FM55 and FM94 melanoma cells respectively, as evidenced by co-localization with
DAPI staining. Low level PTPRF expression in normal epidermal contrasted with higher
expression (both cytoplasmic and nuclear) in melanoma cells. Finally, SHC4 expression
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Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 12/23Figure 2 A new signaling network for melanoma. The signaling network is based on the complex interactions of the 12 signature genes (labeled
in red) and the 4 melanoma driver genes (BRAF, cKit, NRAS, MITF) in 3 signaling pathways (MAPK, Ca2C and WNT). Nine of these 12 genes
(i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, CXCL13, TNC, COL11A1, and SHC4) closely interact with three driver genes (NRAS, BRAF, and MITF)
in the MAPK signaling pathway: the remaining 3 genes include WNT4, PPP2R2C and CHP2, which also play important roles in WNT and Ca2C
signaling pathways.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 13/23Figure 3 Immunocytochemical analysis of human melanocytes and melanoma cells in vitro. COL11A1,
CXCL13, PTPRF and SHC4 proteins were upregulated (green ﬂuorescence) in melanoma cells. Inserts
show higher power views of expression, including when associated with the perinuclear region of the cell.
was membranous in normal melanocytes contrasting with some punctuate nuclear
membraneexpressioninmelanomacells(Fig.3).
The expression of these four proteins was also assessed in normal human healthy
skin and in melanoma patient tissue (both primary and metastatic melanoma). Using
double immunoﬂuorescence with a melanocyte lineage marker gp100, we assessed the
relationship of the four test proteins with melanocytes or melanoma cells in these tumor
biopsies. We included primary melanoma (in addition to metastatic melanoma) in our
immunohistochemistry validation study because the expression levels for the 12 genes in
oursignatureexhibitedseveralfoldlevelchangesbetweenprimarymelanomaandnormal
skin/benignneviacross5microarraydatasets(TableS8).
COL11A1, CXCL13 and PTPRF were not detected in normal human epidermal
melanocytes in situ (Fig. 4a). Some low level expression of SHC4 was detected in these
normal pigment cells. By contrast, COL11A1 was expressed intensely by melanoma cells
located in the dermis of both primary and metastatic melanoma (Fig. 4b). CXCL13
was strongly expressed in a minor subpopulation of tumor cells in primary melanoma,
while a greater fraction of cells in metastatic melanoma tissue expressed this protein. By
contrast,PTPRFwasintenselyexpressedinthemajorityoftumorcellsofbothprimaryand
metastatic melanoma cells. Finally SHC4 was found to be expressed in minor fraction of
primarygp100-positivemelanoma,butinmostmetastaticgp100-positivemelanomacells.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 14/23Figure 4a Immunohistochemical analaysis of COL11A1, CXCL13, PTPRF and SHC4 in normal human
skin epidermis. Melanocytes were detected with an antibody (NKi/beteb) raised against the melanocyte-
speciﬁc marker gp100 (red, arrows). COL11A1, CXCL13, PTPRF (shown in green) were not detected
in normal epidermal melanocytes. SHC4 was expressed strongly in proliferating keratinocytes in the
basal layer on the epidermis, and to some extent also in melanocytes (i.e. double positive cells in
orange-yellow).
Computational evaluation of the robustness of a proposed 12-
gene biomarker signature in distinguishing melanoma from nor-
mal skin and/or benign nevi
A computational evaluation of robustness of the proposed 12-gene signature, based
on melanoma driver gene association, was performed for distinguishing melanoma
from normal skin and/or benign nevi using cross-laboratory published data. This data
evaluationisimportanttoverifytherobustnessofanewbiomarkerforpotentialdiagnostic
application and/or possible therapeutic development. The support vector machine
(so-called SVM model) classiﬁcation model (Brown et al., 2000) and the ‘leave-one-out
method’ are used to classify microarray datasets (Hoek et al., 2004; Smith, Hoek & Becker,
2005; Riker et al., 2008; Scatolini et al., 2010; Rose et al., 2011). Our results showed that
these 12 genes achieved excellent classiﬁcation accuracy ratios across these ﬁve datasets
(i.e.,averageof99.1%,Table4).Thisresultindicatedthatour12-genebiomarkerachieved
a classiﬁcation accuracy ratios that was identical or near identical to the classiﬁcation
accuracy ratios of the original individual studies. Importantly, the 12-gene biomarker
signature achieved a much better performance on average than the signatures of Smith,
Hoek & Becker (2005), Riker et al. (2008) and Scatolini et al. (2010), and very slightly less
(0.44% less) classiﬁcation accuracy than the signature of Hoek et al. (2004). It should be
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 15/23Figure4b Immunohistochemical analaysis of COL11A1, CXCL13, PTPRF and SHC4 in primary and metastatic melanoma. Double staining of test
protein (shown in green) and pigment cell lineage-speciﬁc marker gp100 (in red, arrows). Both immunoreactivites were merged with yellow/orange
ﬂuorescence indicating co-localization of these proteins in melanoma cells.
Table4 Classiﬁcation accuracy of four original signatures on across-laboratory data.
Originalsignatures GSE4570(2004) GSE4587(2005) GSE7553(2008) GSE12391(2010) GSE22301(2011) Average
(Hoek et al., 2004) (589) 100% 100% 97.78% 100% 100% 99.56%
(Smith, Hoek & Becker, 2005)
(100)
71.43% 100% 97.78% 100% 100% 93.84%
(Riker et al., 2008) (65) 71.43% 100% 95.56% 100% 100% 93.40%
(Scatolini et al., 2010) (455) 85.71% 100% 97.78% 100% 100% 96.70%
New 12-gene biomarkers 100% 100% 95.56% 100% 100% 99.11%
noted that the signature of Hoek et al. (2004) consisted of 589 genes, while our biomarker
signatureisverymuchshorteratjust12genes.
DISCUSSION
There is poor congruence between gene signatures generated by diVerent microarray-
based melanoma studies (John et al., 2008; Bittner et al., 2000; T´ ım´ ar, GyorVy & R´ as´ o,
2010). Unsurprisingly therefore, microarray-based melanoma gene biomarkers have
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 16/23Figure5 Experimental protocol of study.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 17/23had poor translation to clinical practice, and melanoma diagnosis is still based on
clinical and histopathological features of the tumor (Schramm et al., 2011). To perform
a meta-analysis on microarray gene expression data, Rhodes et al. (2002) introduced
a model for combination of diVerentially-expressed genes based on their p-value in a
statistical test. Here we propose a new and universally-applicable method to overcome
somelimitationsoftheRhodesmodel(seeMethods).Ournewmethodmeasuresﬁrstlythe
‘genome-widerelativesigniﬁcance’(GWRS)asdeﬁnedinanindividualdatasetfollowedby
a ‘genome-wide global signiﬁcance’ (GWGS) as deﬁned as an assessment across multiple
datasets. The robustness and eVectiveness of our approach can be supported by several
linesofevidenceandvalidation.
First, a considerable number of novel genes (e.g., GTAG1A/1B/2, GAGE1-8/12B-J,
XAGE1A-E, IL8, IGF2/INS-IGF2, SHC4, LEP, TF, CYP3A5, TP63 and GBP5) revealed
by our method were not identiﬁed as signiﬁcant genes in the previous 16 melanoma
microarray studies published between 2000 and 2011, but have still been conﬁrmed as
melanoma-associatedbyindependent‘wet-lab’studiesintheliterature(TableS4).
Second,ourmethodidentiﬁedacoresignatureof12genes(i.e., EGFR, FGFR2, FGFR3,
IL8, PTPRF, TNC, CXCL13, COL11A1, SHC4, CHP2, PPP2R2C and WNT4) that are
closely associated with known melanoma driver genes. However, six signature genes
(i.e., IL8, SHC4, COL11A1, CHP2, PPP2R2C and WNT4) were not reported previously
by microarray-based melanoma studies, although two (i.e. IL8 and SHC4) have been
identiﬁed in independent wet-lab studies (Zhang et al., 2011; Fagiani et al., 2007; Pasini
et al., 2009). This leaves WNT4, CHP2, PPP2R2C and COL11A1 which have not been
previously reported to be associated with melanoma. However, Fedida-Metula recently
suggested a relationship between Ca2C signaling members and PP2A and melanoma
tumor growth (Fedida-Metula et al., 2012). CHP2 (‘calcineurin-like EF hand protein’)
isinvolvedincalciumsignaling,whilePPP2R2C isamemberofthePP2Afamily.
Third, we validated the expression of MAPK-associated members (COL11A1,
CXCL13, PTPRF, SHC4) of the 12-gene biomarkers in a comparative analysis of normal
melanocytes and melanoma cells in vitro and in primary versus metastatic melanoma
biopsy tissue in situ. All four markers were found to be preferentially associated with
melanoma,beingdiVerentiallyexpressedinprimaryandmetastaticmelanoma.Strikingly,
COL11A1, CXCL13, and PTPRF were not detectable in epidermal melanocytes of normal
healthy human skin epidermis. SHC4 was expressed at low levels in normal epidermal
melanocytes,aspreviouslyshown(Fagianietal.,2007).
The over-expression of COL11A1, CXCL13, PTPRF, and SHC4 in melanoma cells in
vitro and in situ may reﬂect the observed over-expression of the associated genes in our
microarray meta-analysis results. The considerably higher level of SHC4 expression in the
perikaryonofmelanomacellsisofnote,andconcurswithotherstudiesshowingrestricted
expression in melanomas, while only weakly expressed in normal melanocytes and
benign nevi (Fagiani et al., 2007). There is evidence that SHC4 is highly expressed at the
transition from radial growth phase to vertical growth phase and metastatic melanomas,
contemporaneous with the acquisition of melanoma migratory competence and invasive
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 18/23potential(Fagianietal.,2007;Pasinietal.,2009).Thisproteintyrosinephosphataseactsas
a signaling molecule to regulate cell growth, diVerentiation, mitotic cycle, and oncogenic
transformation (Junta et al., 2008). PTPRF usually is expressed in the cell membrane
(i.e.isareceptor-typeproteintyrosinephosphatase)whereitinteractswith-cateninand
like -catenin may be translocated to the nucleus upon activation. The over-expression
of COL11A1, CXCL13, PTPRF and SHC4 in our melanoma cell lines and primary and
metastatictissue,andtheirpotentialassociationwithMAPKpathwayssuggeststheycould
bespeciﬁcbiomarkersformelanomaandsopotentialtherapeutictargets.
Our computational evaluation indicates that this new 12-gene biomarker signature
achieves excellent diagnostic power in distinguishing metastatic melanoma from normal
skin and benign nevus. The integrated analysis of these ﬁve microarray datasets has
identiﬁed a robust 12-gene biomarker signature that includes six previously-unreported
genes in melanoma. Further experimental validation of the role of these 12 signature
genes in a revised signaling network may provide new insights into the underlying
biological mechanisms driving the progression of melanoma. Moreover, given that the
original signatures involved much larger numbers of genes (e.g., 589, 100, 65, 455 genes
per signature), an excellent classiﬁcation accuracy ratio performance was achieved by
our melanoma biomarker signature with just 12 genes. This supports the view that our
integrated approach extracts more informative genes than the original signatures, and
from a clinical perspective our 12-gene signature could be a more valuable biomarker for
melanomaintheclinicalsetting.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
The funding for this study was provided by the University of Bradford’s Department of
Computing and Centre for Skin Sciences. The funders had no role in study design, data
collectionandanalysis,decisiontopublish,orpreparationofthemanuscript.
Grant Disclosures
Thefollowinggrantinformationwasdisclosedbytheauthors:
UniversityofBradford’sDepartmentofComputing.
UniversityofBradford’sCentreforSkinSciences.
Competing Interests
Wanting Liu and Yonghong Peng have no competing interests. Des Tobin and Yonghong
PengareAcademicEditorsforPeerJ.
Author Contributions
 WantingLiuperformedtheexperiments,analyzedthedata,wrotethepaper.
 YonghongPengconceivedanddesignedtheexperiments,analyzedthedata,contributed
reagents/materials/analysistools,wrotethepaper.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 19/23 Desmond J. Tobin conceived and designed the experiments, analyzed the data,
contributedreagents/materials/analysistools,wrotethepaper.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/
10.7717/peerj.49.
REFERENCES
Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M,
Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Edgar R. 2011. NCBI GEO: archive
for functional genomics datasets- 10 years on. Nucleic Acids Research 39:D1005–D1010
DOI 10.1093/nar/gkq1184.
Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R,
Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J,
Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M,
Alberts D, Sondak V. 2000. Molecular classiﬁcation of cutaneous malignant melanoma by gene
expression proﬁling. Nature 406:536–540 DOI 10.1038/35020115.
Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Haussler D.
2000. Knowledge-based analysis of microarray gene expression data by using support vector
machines. Proceedings of the National Academy of Sciences of the United States of America
97:262–267 DOI 10.1073/pnas.97.1.262.
Carretero R, Wang E, Rodrguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM,
Marincola FM, Garrido F, Cabrera T. 2011. Regression of melanoma metastases after
immunotherapy is associated with activation of antigen presentation and interferon-mediated
rejection genes. International Journal of Cancer 131:387–395 DOI 10.1002/ijc.26471.
Choi JK, Yu U, Kim S, Yoo OJ. 2003. Combining multiple microarray studies and modeling
interstudy variation. Bioinformatics 19:i84–i91 DOI 10.1093/bioinformatics/btg1010.
Cochran J, Conn VS. 2008. Meta-analysis of quality of life outcomes following diabetes
self-management training. Diabetes Education 34:815–823 DOI 10.1177/0145721708323640.
Eigentler T, Garbe C. 2006. Malignant melanoma: classiﬁcation and staging of malignant
melanoma. Frontiers of Radiation Therapy and Oncology 39:149–158.
Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, Germano G, Bono M,
Capillo M, Pelicci P, Lanfrancone L. 2007. RaLP, a new member of the Src homology and
collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer
Research 67:3064–3073 DOI 10.1158/0008-5472.CAN-06-2301.
Fedida-Metula S, Feldman B, Koshelev V, Levin-Gromiko U, Voronov E, Fishman D. 2012.
Lipid rafts couple store-operated Ca2C entry to constitutive activation of PKB/Akt in a
Ca2C/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth.
Carcinogenesis 33(4):740–750 DOI 10.1093/carcin/bgs021.
Flaherty KT, McArthur G. 2010. BRAF, a target in melanoma: implications for solid tumor drug
development. Cancer 116:4902–4913 DOI 10.1002/cncr.25261.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R,
Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML,
Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival
oncogene ampliﬁed in malignant melanoma. Nature 436:117–122 DOI 10.1038/nature03664.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 20/23Gledhill K, Rhodes LE, Brownrigg M, Haylett AK, Masoodi M, Thody AJ, Nicolaou A, Tobin DJ.
2010. Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to
UVB in a melanogenesis-independent manner. Pigment Cell Melanoma Research 23(3):394–403
DOI 10.1111/j.1755-148X.2010.00696.x.
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. 2006. Examination of mutations in
BRAF, NRAS and PTEN in primary cutaneous melanoma. Journal of Investigative Dermatology
126:154–160 DOI 10.1038/sj.jid.5700026.
Gremel G, RaVerty M, Lau TYK, Gallagher WM. 2009. Identiﬁcation and functional validation
of therapeutic targets for malignant melanoma. Critical Reviews in Oncology/Hematology
72:194–214 DOI 10.1016/j.critrevonc.2009.02.004.
Guntur AR, Reinhold MI, Cuellar JJr, Naski MC. 2011. Conditional ablation of Pten in osteopro-
genitors stimulates FGF signaling. Development 138:1433–1444 DOI 10.1242/dev.058016.
Hocker T, Tsao H. 2007. Ultraviolet radiation and melanoma: a systematic review and analysis of
reported sequence variants. Human Mutation 28:578–588 DOI 10.1002/humu.20481.
Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E,
Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. 2004. Expression
proﬁling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer
Research 64:5270–5282 DOI 10.1158/0008-5472.CAN-04-0731.
Hoek KS. 2007. DNA microarray analysis of melanoma gene expression: a decade in the mines.
Pigment Cell Research 20:466–484 DOI 10.1111/j.1600-0749.2007.00412.x.
Hong F, Breitling R. 2008. A comparison of meta-analysis methods for detecting
diVerentially expressed genes in microarray experiments. Bioinformatics 24:374–382
DOI 10.1093/bioinformatics/btm620.
Hosack DA, Dennis GJr, Sherman BT, Lane HC, Lempicki RA. 2003. Identifying biological
themes within lists of genes with EASE. Genome Biology 4:R70 DOI 10.1186/gb-2003-4-10-r70.
Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. 2007. Gene expression
signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected
melanoma tissue. Clinical Cancer Research 13:806–815 DOI 10.1158/1078-0432.CCR-06-1820.
John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS. 2008.
Predicting clinical outcome through molecular proﬁling in stage III melanoma. Clinical Cancer
Research 14:5173–5180 DOI 10.1158/1078-0432.CCR-07-4170.
Junta CM, Sandrin-Garcia P, Fachin-Saltoratto AL, Mello SS, Oliveira RD, Rassi DM,
Giuliatti S, Sakamoto-Hojo ET, Louzada-Junior P, Donadi EA, Passos GA. 2008. DiVerent
gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may
discriminate immunogenetic, pathogenic and treatment features. Immunology 127:365–372
DOI 10.1111/j.1365-2567.2008.03005.x.
Jurman G, Merler S, Barla A, Paoli S, Galea A, Furlanello C. 2008. Algebraic stability
indicators for ranked lists in molecular proﬁling. Bioinformatics 24:258–264
DOI 10.1093/bioinformatics/btm550.
Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2012. KEGG for integration and
interpretation of large-scale molecular data sets. Nucleic Acids Research 40:D109–D114
DOI 10.1093/nar/gkr988.
Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, Cochran AJ, Binder SW. 2012.
DiVerential gene expression proﬁling of primary cutaneous melanoma and sentinel lymph
node metastases. Modern Pathology 25(6):828–837 DOI 10.1038/modpathol.2012.32.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 21/23Lens M. 2008. Current clinical overview of cutaneous melanoma. British Journal of Nursing
17:300–305.
Lukk M, Kapushesky M, Nikkil¨ a J, Parkinson H, Goncalves A, Huber W, Ukkonen E, Brazma A.
2010. A global map of human gene expression. Nature Biotechnology 28:322–324
DOI 10.1038/nbt0410-322.
Mann GJ, Pupo GM, Campain AE. 2013. BRAF mutation, NRAS mutation and absence of an
immune-related expressed gene proﬁle predict poor outcome in surgically resected stage III
melanoma. Journal of Investigative Dermatology 133:509–517 DOI 10.1038/jid.2012.283.
Miller AJ, Mihm MC. 2006. Mechanisms of Diseases: Melanoma. New England Journal of Medicine
355:51–65 DOI 10.1056/NEJMra052166.
Miyamoto J, Berkowitz Z, Jones SE, Saraiya M. 2012. Indoor tanning device use among
male high school students in the United States. Journal of Adolescent Health 50:308–310
DOI 10.1016/j.jadohealth.2011.08.007.
Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. 2009. c-Kit mutants require
hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29:227–236
DOI 10.1038/onc.2009.320.
Morrison MA, Silveira AC, Huynh N, Jun G, Smith SE, Zacharaki F, Sato H, Loomis S,
Andreoli MT, Adams SM, Radeke MJ, Jelcick AS, Yuan Y, Tsiloulis AN, Chatzoulis DZ,
Silvestri G, Kotoula MG, Tsironi EE, Hollis BW, Chen R, Haider NB, Miller JW, Farrer LA,
Hageman GS, Kim IK, Schaumberg DA, DeAngelis MM. 2011. Systems biology-based analysis
implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular
degeneration. Human Genomics 5:538–568 DOI 10.1186/1479-7364-5-6-538.
Norval M. 2011. The challenges of UV-induced immunomodulation for children’s health. Progress
in Biophysics and Molecular Biology 107:323–332 DOI 10.1016/j.pbiomolbio.2011.07.014.
Park WD, Stegall MD. 2007. A meta-analysis of kidney microarray datasets: investigation of
cytokine gene detection and correlation with RT-PCR and detection threshold. BMC Genomics
8:88 DOI 10.1186/1471-2164-8-88.
Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I,
Hastings E, Holloway E, Kurbatova N, Lukk M, Malone J, Mani R, Pilicheva E, Rustici G,
Sharma A, Williams E, Adamusiak T, Brandizi M, Sklyar N, Brazma A. 2011. ArrayExpress
updata-an archive of microarray and high-throughput sequencing-based functional genomics
experiments. Nucleic Acids Research 39:D1002–D1004 DOI 10.1093/nar/gkq1040.
Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. 2004. A cross-study comparison
of gene expression studies for the molecular classiﬁcation of lung cancer. Clinical Cancer
Research 10:2922–2927 DOI 10.1158/1078-0432.CCR-03-0490.
Pasini L, Turco MY, Luzi L, Aladowicz E, Fagiani E, Lanfrancone L. 2009. Melanoma:
targeting signaling pathways and RaLP. Expert Opinion Therapeutic Targets 13:93–104
DOI 10.1517/14728220802607363.
Phung B, Sun J, Schepsky A, Steingrimsson E, Ronnstrand L. 2011. C-KIT signaling depends
on microphthalmia-associated transcription factor for eVects on cell proliferation. PLoS ONE
6:e24064 DOI 10.1371/journal.pone.0024064.
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T,
Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S,
Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. 2012. Immunologic correlates of
the abscopal eVect in a patient with melanoma. New England Journal of Medicine 366:925–931
DOI 10.1056/NEJMoa1112824.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 22/23Ramasamy A, Mondry A, Holmes CC, Altman DG. 2008. Key issues in conducting a
meta-analysis of gene expression microarray datasets. PLoS Medicine 5:1320–1332
DOI 10.1371/journal.pmed.0050184.
Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. 2002. Meta-analysis of
microarrays: interstudy validation of gene expression proﬁles reveals pathway dysregulation
in prostate cancer. Cancer Research 62:4427–4433.
Rigel DS, Carucci JA. 2000. Malignant melanoma: prevention, early detection, and treatment in
the 21st century. CA: A Cancer Journal for Clinicians 50:215–236 DOI 10.3322/canjclin.50.4.215.
Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS,
Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. 2008. The gene expression proﬁles of
primary and metastatic melanoma yields a transition point of tumor progression and
metastasis. BMC Medical Genomics 1:13 DOI 10.1186/1755-8794-1-13.
Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega Y, Saenz de Miera EC,
Medicherla R, Christos PJ, Shapiro R, Pavlick A, Darvishian F, Zavadil J, Polsky D,
Hernando E, Ostrer H, Osman I. 2011. Integrative genomics identiﬁes molecular alterations
that challenge the linear model of melanoma progression. Cancer Research 71:2561–2571
DOI 10.1158/0008-5472.CAN-10-2958.
Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M,
Chiorino G. 2010. Altered molecular pathways in melanocytic lesions. International Journal
of Cancer 126:1869–1881.
Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ. 2011. Review and cross-validation
of gene expression signatures and melanoma prognosis. Journal of Investigative Dermatology
132:274–283 DOI 10.1038/jid.2011.305.
Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer.
Nature Reviews Cancer 7:295–308 DOI 10.1038/nrc2109.
Smith AP, Hoek K, Becker D. 2005. Whole-genome expression proﬁling of the melanoma
progression pathway reveals marked molecular diVerences between nevi/melanoma in situ
and advanced-stage melanoma. Cancer Biology Therapy 4:1018–1029 DOI 10.4161/cbt.4.9.2165.
Taylor KL, Lister JA, Zeng Z, Ishizaki H, Anderson C, Kelsh RN, Jackson IL, Patton EE. 2011.
DiVerentiated melanocyte cell division occurs in vivo and is promoted by mutations in Mitf.
Development 138:3579–3589 DOI 10.1242/dev.064014.
T´ ım´ ar J, GyorVy B, R´ as´ o E. 2010. Gene signature of the metastatic potential of cutaneous
melanoma: too much for too litter? Clinical and Experimental Metastasis 27:371–387
DOI 10.1007/s10585-010-9307-2.
Wai Wong C, Dye DE, Coombe DR. 2012. The role of immunoglobulin superfamily cell adhesion
molecules in cancer metastasis. International Journal of Cell Biology Volume 2012, Article ID
340296, 9 pages DOI 10.1155/2012/340296.
Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X. 2011. IL8 and
cathepsin B as melanoma serum biomarkers. International Journal of Molecular Sciences
12:1505–1518 DOI 10.3390/ijms12031505.
Liu et al. (2013), PeerJ, DOI 10.7717/peerj.49 23/23